
## Wen-Jun Wei

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8120914/publications.pdf Version: 2024-02-01



WENLIN WEI

#	Article	IF	CITATIONS
1	Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Microcarcinoma: A Study of 1066 Patients. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1250-1257.	3.6	257
2	Confirmation of papillary thyroid cancer susceptibility loci identified by genome-wide association studies of chromosomes 14q13, 9q22, 2q35 and 8p12 in a Chinese population. Journal of Medical Genetics, 2013, 50, 689-695.	3.2	66
3	Histone methyltransferase KMT5A gene modulates oncogenesis and lipid metabolism of papillary thyroid cancer inĀʿÂ;¹⁄2vitro. Oncology Reports, 2018, 39, 2185-2192.	2.6	52
4	Surgical Confirmation of Incomplete Treatment for Primary Papillary Thyroid Carcinoma by Percutaneous Thermal Ablation: A Retrospective Case Review and Literature Review. Thyroid, 2018, 28, 1134-1142.	4.5	52
5	Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 120-132.	3.6	42
6	Association between the rs2910164 Polymorphism in Pre-Mir-146a Sequence and Thyroid Carcinogenesis. PLoS ONE, 2013, 8, e56638.	2.5	37
7	Association of the miR-149 Rs2292832 Polymorphism with Papillary Thyroid Cancer Risk and Clinicopathologic Characteristics in a Chinese Population. International Journal of Molecular Sciences, 2014, 15, 20968-20981.	4.1	34
8	Association study of single nucleotide polymorphisms in mature microRNAs and the risk of thyroid tumor in a Chinese population. Endocrine, 2015, 49, 436-444.	2.3	32
9	Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma. Thyroid, 2019, 29, 1269-1278.	4.5	27
10	The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial. Thyroid, 2021, 31, 1808-1813.	4.5	27
11	The Trend of Age-Group Effect on Prognosis in Differentiated Thyroid Cancer. Scientific Reports, 2016, 6, 27086.	3.3	25
12	Downregulation of <scp>CSN</scp> 6 attenuates papillary thyroid carcinoma progression by reducing Wnt/ <i>l²</i> atenin signaling and sensitizes cancer cells to <scp>FH</scp> 535 therapy. Cancer Medicine, 2018, 7, 285-296.	2.8	23
13	Association between breast cancer and thyroid cancer: A study based on 13Â978 patients with breast cancer. Cancer Medicine, 2018, 7, 6393-6400.	2.8	21
14	An Update of the Appropriate Treatment Strategies in Anaplastic Thyroid Cancer: A Population-Based Study of 735 Patients. International Journal of Endocrinology, 2019, 2019, 1-7.	1.5	20
15	SNHG9, a Papillary Thyroid Cancer Cell Exosome-Enriched IncRNA, Inhibits Cell Autophagy and Promotes Cell Apoptosis of Normal Thyroid Epithelial Cell Nthy-ori-3 Through YBOX3/P21 Pathway. Frontiers in Oncology, 2021, 11, 647034.	2.8	19
16	Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation. Oncology Reports, 2018, 39, 338-348.	2.6	17
17	Clinical significance of papillary thyroid cancer risk loci identified by genome-wide association studies. Cancer Genetics, 2015, 208, 68-75.	0.4	14
18	Prognostic value of primary tumor surgery in minor salivary-gland carcinoma patients with distant metastases at diagnosis: first evidence from a SEER-based study. Cancer Management and Research, 2018, Volume 10, 2163-2172.	1.9	13

Wen-Jun Wei

#	Article	IF	CITATIONS
19	Predictive factors for recurrence of differentiated thyroid cancer in patients under 21Âyears of age and a meta-analysis of the current literature. Tumor Biology, 2016, 37, 7797-7808.	1.8	12
20	The extent of lymph node yield in central neck dissection can be affected by preoperative and intraoperative assessment and alter the prognosis of papillary thyroid carcinoma. Cancer Medicine, 2020, 9, 1017-1024.	2.8	12
21	Risk of malignancy in focal thyroid lesions identified by 18F-fluorodeoxyglucose positron emission tomography/computed tomography: evidence from a large series of studies. Tumor Biology, 2014, 35, 6139-6147.	1.8	11
22	Verteporfin inhibits papillary thyroid cancer cells proliferation and cell cycle through ERK1/2 signaling pathway. Journal of Cancer, 2018, 9, 1329-1336.	2.5	11
23	Prognostic Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients with Major Salivary Cland Mucoepidermoid Carcinoma. Journal of Cancer, 2019, 10, 4380-4388.	2.5	11
24	Lingual ectopic papillary thyroid carcinoma: Two case reports and review of the literature. Oral Oncology, 2019, 88, 186-189.	1.5	11
25	IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis. Diagnostic Pathology, 2019, 14, 52.	2.0	10
26	IL-10 Restores MHC Class I Expression and Interferes With Immunity in Papillary Thyroid Cancer With Hashimoto Thyroiditis. Endocrinology, 2020, 161, .	2.8	10
27	Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma. Frontiers in Endocrinology, 2022, 13, 859013.	3.5	10
28	Relationship of body mass index with BRAF V600E mutation in papillary thyroid cancer. Tumor Biology, 2016, 37, 8383-8390.	1.8	9
29	The Positive Lymph Node Number and Postoperative Nâ€Staging Used to Estimate Survival in Patients with Differentiated Thyroid Cancer: Results from the Surveillance, Epidemiology, and End Results Dataset (1988–2008). World Journal of Surgery, 2018, 42, 1762-1771.	1.6	9
30	NRG1 regulates redox homeostasis via NRF2 in papillary thyroid cancer. International Journal of Oncology, 2018, 53, 685-693.	3.3	9
31	Lymph node ratio (LNR) as a complementary staging system to TNM staging in salivary gland cancer. European Archives of Oto-Rhino-Laryngology, 2019, 276, 3425-3434.	1.6	9
32	Mitotically associated long non-coding RNA is a tumor promoter in anaplastic thyroid cancer. Annals of Translational Medicine, 2020, 8, 1226-1226.	1.7	9
33	IL-2 enhanced MHC class I expression in papillary thyroid cancer with Hashimoto's thyroiditis overcomes immune escape <i> in vitro</i> . Journal of Cancer, 2020, 11, 4250-4260.	2.5	9
34	Arms-qPCR Improves Detection Sensitivity of Earlier Diagnosis of Papillary Thyroid Cancers With Worse Prognosis Determined by Coexisting BRAF V600E and Tert Promoter Mutations. Endocrine Practice, 2021, 27, 698-705.	2.1	8
35	Different clinicopathologic features predispose to different patterns of distant metastasis with heterogeneous shortâ€ŧerm prognosis in patients with differentiated thyroid cancer. Clinical Endocrinology, 2022, 96, 402-412.	2.4	6
36	Silencing of PPM1D inhibits cell proliferation and invasion through the p38�MAPK and p53 signaling pathway in papillary thyroid carcinoma. Oncology Reports, 2020, 43, 783-794.	2.6	6

Wen-Jun Wei

#	Article	IF	CITATIONS
37	Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma. Endocrine, 2022, 76, 660-670.	2.3	6
38	Central Lymph Node Status has Significant Prognostic Value in the Clinically Node-Negative Tall-Cell Variant of Papillary Thyroid Cancer Regardless of T-Staging and Radioactive Iodine Administration: First Evidence From a Population-Based Study. Annals of Surgical Oncology, 2018, 25, 2316-2322.	1.5	5
39	A 4 Gene-based Immune Signature Predicts Dedifferentiation and Immune Exhaustion in Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3208-e3220.	3.6	5
40	PRDM16 Inhibits Cell Proliferation and Migration via Epithelial-to-Mesenchymal Transition by Directly Targeting Pyruvate Carboxylase in Papillary Thyroid Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 723777.	3.7	4
41	Anatomic extent of lymph node metastases as an independent prognosticator in node-positive major salivary gland carcinoma: AÂstudy of the US SEER database and a Chinese multicenter cohort. European Journal of Surgical Oncology, 2019, 45, 2143-2150.	1.0	3
42	Dedifferentiation patterns in DTC: is PDTC an intermediate state between DTC and ATC?. International Journal of Clinical and Experimental Pathology, 2019, 12, 267-274.	0.5	3
43	Multiple lectin assays in detecting glycol-alteration status of serum NRG1 in papillary thyroid cancer. Translational Cancer Research, 2021, 10, 3218-3224.	1.0	2
44	Treating Clinically Node-Negative Insular Thyroid Carcinoma without Prophylactic Central Compartment Neck Dissection Is Associated with Decreased Survival Regardless of T Staging and Administration of Radioactive Iodine Therapy: The First Evidence. International Journal of Endocrinology, 2019, 2019, 1-8.	1.5	0
45	A novel method to reconstruct right recurrent laryngeal nerve by transforming into non recurrent laryngeal nerve: The endâ€ŧoâ€free vagal laryngeal branch end anastomosis. Head and Neck, 2021, , .	2.0	0